ImmunityBio Inc (NASDAQ:IBRX) concluded the trading at $6.06 on Thursday, April 11, with a rise of 1.68% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $5.96 and 5Y monthly beta was reading 0.00. Considering stock’s 52-week price range provides that IBRX hit a high price of $6.93 and saw its price falling to a low level of $1.25 during that period. Over a period of past 1-month, stock came adding 20.00% in its value.
With its current market valuation of $4.08 billion, ImmunityBio Inc is set to declare its quarterly results on Mar 12, 2024 – Mar 16, 2024. Analysts are in estimates of -$0.16 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.68 for 2024 with estimates of that growing to -$0.45 in next year. These estimates are suggesting current year growth of 40.90% for EPS and 33.80% growth next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $20k. They suggested that in the process company could generate revenue of as low as $20k which could climb up to $20k to hit a high. The average estimate is representing a decrease of -94.40% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $9.68 million in 2024, which will be 1,456.30% more from revenue generated by the company last year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review IBRX stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 100% Buy for it.
Digging deeper we become aware of the PEG ratio of the IBRX stock which is currently positioned at 0. It further provides that stock’s current price level is 8.88% away from its 20-day simple moving average and is 22.63% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 60.34 while volatility remained at 7.10% over the past week which changes to 10.05% when measuring it over the past month. Beta is valued at 1.15, while measure of average true range or ATR is currently at 0.51.
Having a second look at ImmunityBio Inc (NASDAQ:IBRX) provides that stock’s average daily trading volume for 3 months was 4.10 million, while it jumped to 3.79 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 670.87 million.
The percentage of outstanding shares held by the insiders is 79.68% while it is 8.49% for the institutional holders. The figures also indicate that as of Mar 15, 2024, number of stock’s short shares was 53.25 million which implies a short ratio of 11.17. This shows up a 7.90% of Short Interest in company’s outstanding shares on the day. In March the standing of shares short improved as it was 47.14 million in the previous month. Addition of 20.72% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
